文献速递介入技术与安全CT

单中心经皮影像引导冷冻消融治疗淋巴结转移的经验

A Single-Institution Experience in Percutaneous Image-Guided Cryoablation of Lymph Node Metastases.
PubMed 文献 · AJR Am J Roentgenol · 2021-04-14

单中心回顾性研究纳入55例患者共61次CT引导冷冻消融,治疗65枚转移性淋巴结,技术成功率98%(60/61),介入放射学会重大并发症发生率3%(2/61),中位随访25个月局部肿瘤控制率82%(53/65),局部进展18%(12/65),中位复发时间11个月。

要点

  • 65枚转移性淋巴结平均短径1.7±1.2 cm,61次冷冻消融技术成功60次(98%)。
  • 介入放射学会重大并发症2例(3%):气胸1例、出血1例。
  • 中位随访25个月(范围1-121个月),局部肿瘤控制53/65(82%),局部进展12/65(18%),中位复发时间11个月。

核心结论

  • 经皮冷冻消融治疗淋巴结转移可行且安全,但需进一步研究评估长期疗效并明确其在肿瘤治疗中的角色。

研究设计与样本

  • 单中心回顾性研究,2006年11月至2019年9月纳入55例患者(42男、13女,平均年龄64±12岁),共61次CT引导冷冻消融,治疗65枚转移性淋巴结;主要终点为技术成功和重大并发症,次要终点为局部进展时间和远处进展时间;并发症按介入放射学会共识指南分级。

诊断标准与关键数值

  • 技术成功定义为60/61次手术(98%);重大并发症按介入放射学会共识指南分级,共2例(3%);局部肿瘤控制为53/65枚(82%),局部进展为12/65枚(18%),中位复发时间11个月。

临床应用与阅片要点

  • 为保护邻近结构采用的辅助操作包括水分离(n=40)、输尿管支架置入(n=3)和神经监测(n=3);作者认为经皮冷冻消融治疗淋巴结转移可行且安全,需进一步研究评估长期疗效并明确其在肿瘤治疗中的角色。

局限性

  • 原文为单中心回顾性研究;作者指出需进一步研究评估该技术的长期疗效并明确其在肿瘤治疗中的角色。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. The purpose of this study was to assess the feasibility, safety, and efficacy of percutaneous cryoablation for the treatment of lymph node metastases. MATERIALS AND METHODS. In this single-institution retrospective study 55 patients were identified who underwent CT-guided cryoablation of metastatic lymph nodes between November 2006 and September 2019. Patient demographics, disease characteristics, and procedural details were recorded. The primary endpoints were technical success and major complications. The secondary endpoints were time to local and time to distant progression. Complications were graded according to the Society of Interventional Radiology consensus guidelines. RESULTS. The study sample comprised 55 patients (42 men, 13 women; mean age 64 ± 12 years) who underwent 61 cryoablation procedures to treat 65 lymph node metastases. Targeted nodes measured 1.7 ± 1.2 cm in mean short-axis diameter. Technical success was achieved in 60 of 61 cryoablation procedures (98%). Adjunctive maneuvers performed to protect adjacent structures included hydrodissection (n = 40), ureteral stenting (n = 3), and neural monitoring (n = 3). There were two Society of Interventional Radiology major complications (3%): pneumothorax (n = 1) and bleeding (n = 1). Local tumor control was achieved in treatment of 53 of 65 (82%) nodal metastases within a median of 25 months (range, 1-121 months) of follow-up. Local progression occurred in 12 of 65 cases (18%); the median time to recurrence was 11 months. CONCLUSION. Percutaneous cryoablation of nodal metastases is feasible and safe. Further investigation is warranted to assess the long-term efficacy of this technique and to define its role in oncologic care.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Parvinian A, Schmitz JJ, Welch BT, et al. A Single-Institution Experience in Percutaneous Image-Guided Cryoablation of Lymph Node Metastases. AJR Am J Roentgenol. 2021. PMID: 33852333. doi:10.2214/AJR.20.22861

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。